IL124828A0 - Hyaluronic acid receptors binding agents and the use thereof - Google Patents

Hyaluronic acid receptors binding agents and the use thereof

Info

Publication number
IL124828A0
IL124828A0 IL12482896A IL12482896A IL124828A0 IL 124828 A0 IL124828 A0 IL 124828A0 IL 12482896 A IL12482896 A IL 12482896A IL 12482896 A IL12482896 A IL 12482896A IL 124828 A0 IL124828 A0 IL 124828A0
Authority
IL
Israel
Prior art keywords
cac
arg
identified
amino acids
letter code
Prior art date
Application number
IL12482896A
Other languages
English (en)
Original Assignee
Hyal Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyal Pharma Corp filed Critical Hyal Pharma Corp
Publication of IL124828A0 publication Critical patent/IL124828A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/117Esters of phosphoric acids with cycloaliphatic alcohols
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70585CD44
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
IL12482896A 1995-12-27 1996-12-23 Hyaluronic acid receptors binding agents and the use thereof IL124828A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002166155A CA2166155C (en) 1995-12-27 1995-12-27 Agents binding to hyaluronic acid binding domains and the use thereof
PCT/CA1996/000870 WO1997024111A2 (en) 1995-12-27 1996-12-23 Novel hyaluronic acid receptors binding agents and the use thereof

Publications (1)

Publication Number Publication Date
IL124828A0 true IL124828A0 (en) 1999-01-26

Family

ID=4157242

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12482896A IL124828A0 (en) 1995-12-27 1996-12-23 Hyaluronic acid receptors binding agents and the use thereof

Country Status (15)

Country Link
EP (1) EP0874624B1 (de)
JP (1) JP4210330B2 (de)
KR (1) KR100476782B1 (de)
AT (1) ATE255411T1 (de)
AU (1) AU725478B2 (de)
BR (1) BR9612355A (de)
CA (1) CA2166155C (de)
DE (1) DE69630974T2 (de)
ES (1) ES2211996T3 (de)
HU (1) HU226598B1 (de)
IL (1) IL124828A0 (de)
NO (1) NO982935L (de)
PL (1) PL327542A1 (de)
WO (1) WO1997024111A2 (de)
ZA (1) ZA9610840B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2237051A1 (en) * 1997-12-19 1999-06-19 Eva A. Turley Enhanced affinity hyaluronan binding peptides
SE0101854L (sv) * 2001-05-28 2002-11-29 Bioneris Ab Användning av en förening med en negativt laddad region av grupper för behandling av restenos.
WO2004060404A1 (ja) * 2002-12-27 2004-07-22 Chugai Seiyaku Kabushiki Kaisha 薬物担体
EP1896386B1 (de) * 2005-06-08 2012-09-05 Cangene Corporation Hyaluronsäurebindende peptide fördern die immunabwehr gegen pathogene bakterien
RU2012157597A (ru) 2010-05-31 2014-07-20 Лондон Хелс Сайенсис Сентр Рисерч Инк. Rhamm-связывающие пептиды
KR101383941B1 (ko) 2012-03-09 2014-04-10 동아에스티 주식회사 피록시캄 또는 약제학적으로 허용되는 그의 염과 히알루론산 또는 약제학적으로 허용되는 그의 염의 안정한 액상 조성물 및 그 제조방법
US10766927B2 (en) 2012-11-25 2020-09-08 The Regents Of The University Of California Peptides that stimulate subcutaneous adipogenesis
WO2015184125A1 (en) 2014-05-28 2015-12-03 The Regents Of The University Of California Peptides, compositions, and methods for stimulating subcutaneous adipogenesis
US10562935B2 (en) 2015-03-20 2020-02-18 London Health Sciences Centre Research Inc. Stapled peptides and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
CA2122551A1 (en) * 1994-04-29 1995-10-30 Rudolf Edgar Falk Clearing of atherosclerosis
GB9207949D0 (en) * 1992-04-09 1992-05-27 Univ Manitoba Molecular cloning of a novel hyaluronan receptor that mediates tumor cell motility
AU3159595A (en) * 1994-08-30 1996-03-22 Hyal Pharmaceutical Corporation Hyaluronic acid and derivatives for modulation of cellular activity

Also Published As

Publication number Publication date
WO1997024111A3 (en) 1997-10-02
NO982935L (no) 1998-08-27
AU1091297A (en) 1997-07-28
PL327542A1 (en) 1998-12-21
CA2166155A1 (en) 1997-06-28
DE69630974T2 (de) 2004-10-28
HUP9902059A3 (en) 2000-07-28
CA2166155C (en) 2008-02-05
EP0874624A2 (de) 1998-11-04
JP2000506502A (ja) 2000-05-30
ATE255411T1 (de) 2003-12-15
DE69630974D1 (de) 2004-01-15
AU725478B2 (en) 2000-10-12
ES2211996T3 (es) 2004-07-16
ZA9610840B (en) 1997-06-27
BR9612355A (pt) 1999-12-28
JP4210330B2 (ja) 2009-01-14
NO982935D0 (no) 1998-06-24
WO1997024111A2 (en) 1997-07-10
HUP9902059A2 (hu) 2000-04-28
KR100476782B1 (ko) 2005-07-18
KR19990072058A (ko) 1999-09-27
EP0874624B1 (de) 2003-12-03
HU226598B1 (hu) 2009-04-28

Similar Documents

Publication Publication Date Title
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
ATE434447T1 (de) Zusammensetzungen und verfahren zur erzeugung von gefässeokklusion
HUT77380A (hu) Kombinált gyógyszerkészítmény alkalmazása sclerosis multiplex (MS) és más demielizáló állapotok kezelésére
EP0830138A4 (de) Verwendung von fibroblasten-wachstumsfaktoren zur stimulation des knochenwachstums
ATE185268T1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
WO2001036510A3 (en) Use of poly(diallylamine) polymers
MY118652A (en) Use of diazepines for preparing medicines for treating pathological conditions or diseases involving one of the growth hormone release inhibiting factor receptors
WO2000021548A3 (en) Angiogenically effective unit dose of fgf and method of administering
DE69530308D1 (de) Verfahren zur herstellung von dosierungsformen durch feuchtgranulierung
WO1999004772A3 (en) Use of levobupivacaine
CA2154103A1 (en) Treatment of Mucous Membrane Disease, Trauma or Condition and for the Relief of Pain
IL124828A0 (en) Hyaluronic acid receptors binding agents and the use thereof
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
IL127044A0 (en) Use of p-aminophenol derivatives for the preparation of pharmaceutical compositions useful in the treatment of neurodegenerative diseases
CA2225788A1 (en) Therapeutic agents and autoimmune diseases
BR0105776A (pt) Tratamento de combinação para a depressão,a ansiedade e a psicose
BR0111002A (pt) Combinação de secretagogos do hormÈnio do crescimento e antidepressivos
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
YU60199A (sh) Nove soli bpc peptida sa organo-zaštitnom aktivnošću, postupak za njihovo dobijanje i njihova primena u terapiji
EP0743068A3 (de) Zusammensetzung zur Hemmung von Knochenverlust welche Vanadylsulfat enthält
EP1039931A4 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
IL132354A0 (en) Use of cartilage oligomeric matrix protein for the treatment of rheumatoid arthritis
KR950704358A (ko) 카텝신 l 특이적 저해 폴리펩티드

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired